Clinical Trials Browser

Phase 2 × INDUSTRY × eribulin × Clear all

Breast Neoplasms, Neoplasm Metastasis

NCT05458674 2026-04-03

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

Phase 2 Recruiting

30 enrolled

Breast

Breast Neoplasms

NCT06875128 2026-03-13

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

Phase 2 Recruiting

90 enrolled

Breast

Breast Neoplasms

NCT06449222 2026-02-25

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

Phase 2 Active not recruiting

83 enrolled

Breast

Triple Negative Breast Neoplasms

NCT00879086 2023-06-22

A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer

Phase 2 Completed

104 enrolled 16 charts

Breast

Breast Neoplasms, Neoplasms

NCT01104155 2023-06-22

Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer

Phase 2 Completed

123 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01268150 2023-06-22

A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

Phase 2 Completed

56 enrolled 10 charts

Breast

Breast Neoplasms

NCT01269346 2023-06-22

Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer

Phase 2 Completed

52 enrolled 9 charts

Breast

Breast Neoplasms

NCT01439282 2023-06-22

Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer

Phase 2 Completed

77 enrolled 9 charts

Breast

Breast Neoplasms

NCT03441360 2022-10-05

Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)

Phase 2 Completed

23 enrolled 14 charts

Sarcoma

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing

NCT01328249 2019-08-20

Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer

Phase 2 Completed

81 enrolled 9 charts

Breast

Breast Neoplasms

NCT02481050 2018-11-15

Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer

Phase 2 Completed

58 enrolled 14 charts

Breast

Breast Neoplasms

NCT00413192 2017-04-26

E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma

Phase 2 Completed

128 enrolled 16 charts

Sarcoma

NCT01427933 2017-02-06

A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer

Phase 2 Completed

141 enrolled 15 charts

Breast

Breast Neoplasms

NCT01458249 2016-03-28

An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217)

Phase 2 Completed

52 enrolled 13 charts

Sarcoma

NCT00246090 2014-07-14

A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine

Phase 2 Completed

298 enrolled 8 charts

Breast

Breast Neoplasms

NCT00278993 2014-07-14

Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy

Phase 2 Completed

108 enrolled 11 charts

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00965523 2013-08-15

Study of E7389 for Advanced or Metastatic Breast Cancer

Phase 2 Completed

81 enrolled 7 charts

Breast

Breast Neoplasms, Neoplasms

NCT00097721 2013-04-22

A Study of E7389 in Advanced/Metastatic Breast Cancer Patients

Phase 2 Completed

104 enrolled 12 charts

Breast

Breast Neoplasms

NCT00100932 2012-03-27

Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy

Phase 2 Completed

106 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

ASPEN-09-03

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer

Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer

A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer

Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer

Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)

Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer

Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer

E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma

A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer

An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217)

A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine

Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy

Study of E7389 for Advanced or Metastatic Breast Cancer

A Study of E7389 in Advanced/Metastatic Breast Cancer Patients

Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy